Phaseolus vulgaris L. Extract: Alpha-amylase inhibition against metabolic syndrome in mice by Micheli, L. et al.
nutrients
Article
Phaseolus vulgaris L. Extract: Alpha-Amylase
Inhibition against Metabolic Syndrome in Mice
Laura Micheli 1, Elena Lucarini 1 , Elena Trallori 1, Carmen Avagliano 2, Carmen De Caro 3,
Roberto Russo 2, Antonio Calignano 2, Carla Ghelardini 1, Alessandra Pacini 4,† and
Lorenzo Di Cesare Mannelli 1,*,†
1 Department of Neuroscience, Psychology, Drug Research and Child Health-Neurofarba-Pharmacology and
Toxicology Section, University of Florence, 50139 Florence, Italy
2 Department of Pharmacy, University of Naples “Federico II” Naples, 80131 Naples, Italy
3 Department of Science of Health, School of Medicine and Surgery, University of Catanzaro, 88100 Catanzaro,
Italy
4 Department of Experimental and Clinical Medicine, Anatomy and Histology Section, University of Florence,
50134 Florence, Italy
* Correspondence: lorenzo.mannelli@unifi.it; Tel.: +39-055-275-8395
† These authors contribute equally to this work.
Received: 21 June 2019; Accepted: 29 July 2019; Published: 1 August 2019


Abstract: To examine the effects of the alpha-amylase inhibitor isoform 1 called phaseolamin, a
standardized extract from white kidney beans (Phaseolus vulgaris L.) was tested against the hallmarks
of metabolic syndrome. The efficacy of a per os repeated treatment with P. vulgaris extract (500 mg/kg)
was compared with metformin (100 mg/kg) and atorvastatin (10 mg/kg) in a model of metabolic
syndrome evoked by prolonged high fat diet (HFD; week 1 to week 19) in C57BL/6 mice. Bean extract
and compounds administration started after metabolic syndrome establishment (week 11). P. vulgaris
extract reduced the body weight overtime, as well as effectively lowered glycaemia, triglycerides, and
cholesterol. On week 19, bean extract normalized the HFD-evoked tolerance to glucose and insulin.
According to the phytochemical characterization, it inhibited the alpha-amylase activity. Animals
treated with the extract were rescued from motor impairments and nociceptive threshold alterations
induced by HFD. Specific organs analysis revealed that P. vulgaris extract decreased hepatic steatosis
and lipid peroxidation in liver. It protected the heart from HFD oxidative alterations increasing
the expression of the detoxifying enzymes catalase and glutathione reductase, and normalizing
NADH dehydrogenase level. The histological analysis of aorta showed a protection about the
development of fatty streaks in the muscular layers. In conclusion, a prolonged treatment with the
standardized extract of P. vulgaris significantly reduced several pathological features related to a
metabolic syndrome-like condition; a multifactorial approach that candidates this vegetal product as
a possible therapeutic option against metabolic syndrome.
Keywords: P. vulgaris extract; metabolic syndrome; HFD, alpha-amylase inhibitor
1. Introduction
Metabolic syndrome was first described by [1], who named it “Syndrome X”. Since then, the
interest from the investigators has increased constantly, and many were the names given to it, e.g., the
insulin-resistance syndrome, the hypertriglyceridemic waist, and metabolic syndrome. The latter, the
most used term in the cardiovascular field, will be used in this article to refer to this syndrome [2].
The syndrome is a group of co-occurring and interconnected biochemical and metabolic
disorders, among which the hallmarks are altered glucose metabolism, insulin resistance, dyslipidemia,
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hypertension, abdominal obesity, hepatic steatosis, and hypercholesterolemia. The modern lifestyle,
defined by over-nutrition and very little physical exercise, has recently increased its incidence. The array
of disorders which compose metabolic syndrome often represent the preparatory soil for type 2 diabetes
and atherogenic cardiovascular diseases [2–4].
Treatment strategies for metabolic syndrome could involve the use of nutraceuticals, most of
which have plant origins (phytochemicals) associated with lifestyle improvement [5,6].
The pancreatic alpha-amylase inhibitor isoform 1 (alpha-AI 1), also known as phaseolamin, is a
constituent protein of the common white and kidney beans (Phaseolus vulgaris L.). Next to it, there
are two other isoforms and an alpha-amylase inhibitor like (alpha-AI 2, alpha-AI 3 and alpha-AIL,
respectively). The most widely distributed in the plant is the alpha-AI 1, which represents about one
tenth of the total seed protein content [7]. This enzyme hampers the activity of some mammalian and
insect alpha-amylase, but it does not affect the plant endogenous enzyme. Interestingly, each variety of
P. vulgaris produces an alpha-AI type 1 with a fairly different primary structure; nevertheless, all the
enzymes show the same inhibitory activity on animal amylases [8]. This enzyme was discovered in 1945
by [9], and was characterized and named “phaseolamin” in 1975 by [10]. Since then, phaseolamin was
tested for its efficacy as a starch blocker and purified extracts were used as human dietary supplements
with anti-hyperglycaemic and anti-obesity purpose [11]. The results were not as expected, probably
because of an insufficient inhibitory activity on human alpha-amylase. The successive progresses
made in the protein extraction, purification, and standardization fields have allowed the production of
bean plant extracts with higher and more effective inhibitory activity on carbohydrate metabolism [7].
Moreover, although P. vulgaris is not the only plant to contain alpha-amylase inhibitors, as some
cereal plants also produce them, there is no report about severe side effects correlated to its alpha-AIs,
while the cereal-derived isoforms are associated with dermatitis and asthma [7].
The aim of the present study was to evaluate the efficacy of a chronic treatment with a standardized
seed extract from P. vulgaris, containing 6% of the non-nutritive bioactive compound phaseolamin on a
murine model of metabolic syndrome to compare its efficacy to a chronic treatment with two reference
drugs for hyperglycaemia and hypercholesterolemia—i.e., metformin and atorvastatin, respectively.
The metabolic disorders were induced by feeding with a high fat diet (HFD), containing 60% fats out
of total calories, and the results were compared with those obtained from mice fed with normal diet.
HFD-fed animals, indeed, reached the pathological state after 11 weeks of enriched alimentation, as
confirmed by remarkably altered blood levels of glucose, triglycerides, and cholesterol. Further ex
vivo analysis completed the investigation on the grade of regression of the disease reached, following
each treatment.
2. Materials and Methods
2.1. Animals
Male C57BL/6 mice (Envigo, Varese, Italy) weighing approximately 20 g at the beginning of the
experimental procedure were used. Animals were used in Ce.S.A.L (Centro Stabulazione Animali da
Laboratorio, University of Florence) and used at least one week after their arrival. Twelve mice were
housed per cage (size 26 × 41 cm), kept at 23.0 ± 1.0 ◦C with a 12 h light/dark cycle, with lights on at
7 a.m.; during acclimatization they were fed a standard laboratory diet and tap water ad libitum.
All animal manipulations were carried out according to the Directive 2010/63/EU of the European
parliament and of the European Union council (22 September 2010) on the protection of animals used
for scientific purposes. The ethical policy of the University of Florence complies with the Guide for
the Care and Use of Laboratory Animals of the US National Institutes of Health (NIH Publication no.
85–23, revised 1996; University of Florence assurance number: A5278-01). Formal approval to conduct
the experiments described was obtained from the Animal Subjects Review Board of the University of
Florence. Experiments involving animals have been reported according to ARRIVE guidelines [12].
All efforts were made to minimize animal suffering and to reduce the number of animals used.
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2.2. Induction of Metabolic Syndrome
Metabolic syndrome was induced by feeding the animals with a high fat diet (HFD; Research Diets,
New Brunswick, NJ) for 19 weeks ad libitum. The model is consistent, with minor modification, to what
was previously published [13–15]. The HFD contained 60% fat, 20% protein, and 20% carbohydrate, as
a percentage of total Kcal [16]. Control animals were fed ad libitum for 19 weeks with a standard diet
(24% protein, 58% carbohydrate, 18% fat; Envigo, Varese, Italy).
2.3. Extract Preparation
The vegetal extract used in the present study (Beanblock®; Indena S.p.A., Milan, Italy) is a
standardized dry extract containing an alpha-amylase inhibitor and phytohaemagglutinin. Briefly,
P. vulgaris dry extract was prepared by means of aqueous extraction and alcoholic precipitation from
the common kidney bean (P. vulgaris). Bean extract was obtained by extraction with citrate buffer
and precipitation with ethanol. The extract is characterized by a standardized composition of 8.5%
(w/w) tested α-amylase inhibitor, with inhibiting activity = 1400 U/mg, and phytohaemagglutinin
(haemagglutinating activity 16 haemagglutinating units/mg). The manufacturing process is described
in detail by [17,18].
2.4. Treatments
P. vulgaris dry extract 500 mg kg−1 (Indena S.p.A.), metformin 100 mg kg−1 (Carbosynth, UK),
and atorvastatin 10 mg kg−1 (Carbosynth, UK) were suspended in 1% carboxymethylcellulose sodium
salt (CMC; Sigma-Aldrich) and daily per os administered 30 min before the dark phase of the circadian
light/dark cycle in the animal facility from week 11 until week 19. The doses of P. vulgaris, metformin,
and atorvastatin were chosen on the basis of the literature [18–20].
2.5. Body Weight and Food Intake
During the experiment, the body weight of mice was measured every 3 days, while the food
intake was measured weekly.
2.6. Collection of Blood and Analytical Methods
Blood was collected from the facial vein of fed mice under light ether anaesthesia into eppendorf
tubes containing heparin (20 µL, 25,000 IU/5 mL) twice a month, starting from week. Samples were
analyzed for glucose, triglycerides, and total cholesterol levels using a Reflotron reflectance photometric
analyser (Reflotron, Roche Diagnostics and Vitros, Johnson & Johnson). Low-density lipoprotein (LDL),
high-density lipoprotein (HDL) cholesterol, and alpha-amylase activity were measured using the same
method only in week 19. Plasmatic levels of ghrelin and insulin were measured in week 19 using
ELISA kit (Wide range mouse insulin immunoassay kit, Biorbyt; Mouse ghrelin enzyme immunoassay
kit, Biorbyt). Alpha-amylase activity was measured.
2.7. Glucose and Insulin Tolerance Tests
On week 19, the glucose tolerance test (GTT) and the insulin tolerance test (ITT) were performed
by intraperitoneal injections of glucose (1 mg kg−1) and insulin (1 U kg−1; Humalog, Lilly) on fed
animals, respectively. Blood glucose was measured by Accu-Check Aviva at 0 min, 15 min, and 30 min
after glucose injections for GTT, and at 0 min, 30 min, and 60 min after insulin injection for ITT.
2.8. Behavioral Tests
On week 19, the motor coordination was measured by the Rota rod test according to [21].
Mechanical allodynia was measured by Von Frey test as described by [22]. TheHargreaves’ Plantar test
was used to measure the thermal nociceptive threshold as described by [23]. To evaluate anxiety-related
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behavior, the Elevated plus maze test was conducted as previously described by [24,25]. More details
in the Supplementary Materials.
2.9. Tissues Explant
On week 19, after the behavioral measurements and the biochemical analysis, mice were sacrificed
by cervical dislocation and tissues explant was performed. In particular, brain, liver, heart, aorta,
epidydimal white adipose tissue, and kidney were collected.
2.10. Liver and Kidney Histopathology
Samples were fixed in 4% formalin and processed for embedding and sectioning. More details in
the Supplementary Materials.
2.11. Analysis of Lipid Deposition in the Arterial Wall
The aortas were washed with phosphate-buffered saline (PBS) and then fixed with 4%
paraformaldehyde overnight. The proximal aorta attached to the heart was used to prepare cryo-sections.
Cryo-sections (8 µm) were cut, collected, and stained with oil red O according to [26] with minor
modification. The quantification of stained lipids was determined by calculating the positive area in
comparison to the total cross-sectional vessel wall area by using Image-Pro Plus software 4.5 (Media
Cybernetics). The percentage was calculated from five sections for each animal.
2.12. Lipid Peroxidation (Thiobarbituric Acid-Reactive Substances Assay)
Thiobarbituric acid-reactive substances (TBARS) assay was assessed as an index of lipid
peroxidation according to [27]. More details in the Supplementary Materials.
2.13. Carbonylated Proteins
Carbonylated proteins were evaluated in plasma and heart tissue homogenate. Plasma or heart
tissue protein extracts were quantified by BCA. Twenty micrograms of each sample were denatured by
6% SDS and derivatized by 15-min incubation with 2-4 dinitrophenyl hydrazine (DNPH; Sigma-Aldrich,
Italy) at room temperature. More details in the Supplementary Materials.
2.14. Western Blot Analysis
Hearts were homogenized in lysis buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM
EDTA, 0.5% Triton X-100, and Complete Protease Inhibitor (Roche), and the homogenate was incubated
on ice for 30 min. More details in the Supplementary Materials.
2.15. Statistical Analysis
Measurements were performed on a total of 12 animals for each group, analyzed in 2 different
experimental sets (each experimental set was conducted on 6 animals) by researchers blinded to the
treatment procedure. Results were expressed as means ± S.E.M. (standard error of mean) of the
two experiments and the analysis of variance was performed by one-way or two-way ANOVA tests
(Figure 1, Figure 2 and Figure 4). A Bonferroni’s significant difference procedure was used as a post
hoc comparison, and p-values less than 0.05 were considered significant. Data were analyzed using the
“Origin 8.1” software (Northampton, MA, USA).
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Figure 1. Body weight and food intake. Mice were fed with a normal or a high fat diet (HFD) for
139 days. From day 77 (week 11), the animals were treated daily with vehicle (CMC 1%), P. vulgaris
extract 500 mg/kg per os (p.o.), metformin 100 mg/kg p.o., and atorvastatin 10 mg/kg p.o. (a,b) Animals’
body weight evolution, and (c) Animals’ food intake evolution. Red arrows point to the beginning of
compound administration (day 77, week 11). Each value represents the mean ± S.E.M. of 12 mice per
group. ** p < 0.01 vs. normal diet + vehicle; ˆˆ p < 0.01 vs. HFD + vehicle.
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Figure 2. Glucose and insulin tolerance and α-amylase activity. (a) Effects of HFD and treatments on
glucose tolerance test at week 19; blood glucose was measured before the test (pre-test), and 15 and 30
min after the test. (b) Effects of HFD and treatments on insulin tolerance test at week 19. Glucose blood
dosages were performed before the test (pre-test), and 30 and 60 min after the test. (c) Effects of HFD
and treatments on the activity of α-amylase (U/L) in plasmatic sample from animals at week 19. Each
value represents the mean ± S.E.M. of 12 mice per group. ** p < 0.01 vs. group normal diet + vehicle; ˆ
p < 0.05 and ˆˆ p < 0.01 vs. HFD + vehicle; ◦ p < 0.05 vs. pre-test of the same group.
3. Results
3.1. Treatments, Body Weight, and Food Intake
C57BL/6 mice were fed with either a normal diet or a high fat diet (HFD) for 19 weeks. Throughout
all this time, many parameters were periodically assessed: Body weight, food intake, hematic levels
of glucose, triglycerides, and total cholesterol. From the eleventh week on, the mice fed with a high
fat diet were divided into three groups and treated with P. vulgaris extract 500 mg/kg, metformin
100 mg/kg, and atorvastatin 10 mg/kg. Control groups of both types of feeding were challenged with
the vehicle alone (CMC 1%). The drugs, the food extract, and the vehicle were administered daily per
os (p.o.), 30 min before the dark phase of the circadian light/dark cycle of mice in the animal facility.
Figure 1a,b shows the effects of diet and treatments on body weight of each experimental group
from the beginning of the feeding, with a normal or a high fat diet, until the end of the experiment.
On day 0, the body weight mean was homogeneous among all groups, but from day 28 a significant
rise was evident in all groups fed with a HFD diet, with respect to the group fed with standard diet
(31.3 ± 0.7 g vs. 27.8 ± 0.6 g, respectively). The body weight increase of HFD animals remained
significant compared to control animals, from the first compounds challenge until the last experimental
week. However, P. vulgaris extract administration induced a statistically significant weight reduction
in HFD mice between day 85 (week 12) and day 139 (week 19) (Figure 1b), corresponding to an
average 5 g loss in comparison with non-treated animals (47.3 ± 0.36 g vs. 42.5 ± 0.31 g, respectively).
Metformin treatment pointed out a reducing trend in body weight, but eventually it did not reach a
statistical significance, while animals given atorvastatin did not show a different weight in comparison
to the HFD diet control group (Figure 1b).
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Food intake was monitored weekly between the sixth and the 20th weeks (Figure 1c). The normal
diet fed group consumed more food than the HFD animals, a trend which did not change throughout
the whole experiment. Neither an increase nor a decrease in food intake was observed after week 11,
the beginning week of treatments.
3.2. Hematic Metabolic Parameters
By this time, blood dosages of total cholesterol, triglycerides, and glucose were measured twice
a month. Before the administration of the substances, the above-mentioned hematic parameters
were significantly augmented in the high fat diet-fed animals, compared to the control animals
(Supplementary Table S1).
In week 13, after two weeks of treatment, P. vulgaris extract and atorvastatin reduced total
cholesterol levels by 24% and 30%, respectively. This result was constant with statistical significance
until the nineteenth week (Table 1). During these last seven days, HDL and LDL levels were also
measured. The fat-enriched feeding did not alter HDL values in comparison to control animals, while
it increased LDL levels, which were lowered by each treatment. The highest efficacy was reached by P.
vulgaris extract treatments, which almost halved them.
Table 1. Hematic parameters.
Group
Week Normal Diet +Vehicle
HFD +
Vehicle
HFD +
P. vulgaris
HFD +
Metformin
HFD +
Atorvastatin
Glucose (mg/dL)
13 101.0 ± 3.4 139.3 ± 6.9 * 103.0 ± 5.1ˆ 132.0 ± 9.9 133.0 ± 6.2
15 99.0 ± 10.1 149.5 ± 3.9 ** 103.0 ± 8.0ˆˆ 113.3 ± 7.4 ˆ 112.8 ± 7.1 ˆ
17 103.3 ± 6.4 138.5 ± 9.1 * 127.8 ± 2.0 ˆˆ 121.0 ± 5.9 ˆ 146.3 ± 5.5
19 99.3 ± 4.6 137.3 ± 9.4 ** 112.0 ± 4.4 ˆ 116.3 ± 5.7 ˆ 137.3 ± 14.0
Triglycerides
(mg/dL)
13 62.0 ± 6.9 132.3 ± 11.3 * 123.0 ± 18.0 105.0 ± 14.6 102.0 ± 9.0 ˆ
15 72.3 ± 13.6 135.3 ± 6.0 ** 86.5 ± 10.7 ˆ 93.3 ± 10.4 ˆ 103.3 ± 9.4 ˆ
17 78.4 ± 2.7 136.8 ± 2.3 ** 105.3 ± 7.8 ˆˆ 113.8 ± 5.8 ˆ 108.8 ± 7.2 ˆˆ
19 75.8 ± 11.0 133.5 ± 7.7 ** 107.5 ± 9.3 ˆˆ 118.3 ± 3.7 104.0 ± 3.0 ˆˆ
Total cholesterol
(mg/dL)
13 <100 133.7 ± 4.4 ** 104.3 ± 3.5 ˆˆ 128.6 ± 8.2 105.0 ± 6.0 ˆˆ
15 105.0 ± 5.0 135.8 ± 1.3 ** 103.0 ± 2.3 ˆˆ 118.3 ± 7.2 105.0 ± 4.3 ˆˆ
17 107.0 ± 1.2 147.0 ± 2.8 ** 123.0 ± 6.4 ˆˆ 139.3 ± 12.5 109.5 ± 5.0 ˆˆ
19 103.8 ± 4.1 147.3 ± 4.1 ** 100.5 ± 7.6 ˆˆ 103.9 ± 9.2 ˆˆ 76.4 ± 1.4 ˆˆ
HDL (mg/dL) 19 51.8 ± 8.5 62.3 ± 7.0 41.7 ± 10.2 59.1 ± 10.5 46.8 ± 9.5
LDL
(mg/dL) 19 43.8 ± 6.7 62.3 ± 7.0 38.4 ± 6.3 ˆˆ 46.0 ± 9.4 ˆ 50.2 ± 3.0 ˆˆ
Effects of HFD and treatments on glucose, triglycerides, and total cholesterol blood concentration at weeks 13, 15, 17,
and 19. At week 19, HDL and LDL values were also assessed. Animals were fed with normal or HFD diets from
week 1. P. vulgaris extract (500 mg/kg), metformin (100 mg/kg), and atorvastatin (10 mg/kg) were administered daily
per os, starting from week 11. Each value represents the mean ± S.E.M. of at least 12 mice per group. * p < 0.05 and
** p < 0.01 vs. normal diet + vehicle; ˆ p < 0.05 and ˆˆ p < 0.01 vs. HFD + vehicle.
Triglycerides were lowered from the first challenge only by atorvastatin (by 22%), while P. vulgaris
and metformin administrations began to be effective from week 15, until week 19 and week 17,
respectively, inducing results similar to those obtained by atorvastatin injections (Table 1). As to
hematic glucose levels, they were reduced by the administration of P. vulgaris extract and metformin,
by about a fifth and a sixth, respectively. Atorvastatin appeared to be non-effective (Table 1).
3.3. Glucose and Insulin Tolerance Test
The results of the glucose tolerance test (GTT) performed at week 19 are displayed in Figure 2a.
Glucose tolerance is shown by the HFD control animals, whose maximum glycaemic peak, reached
30 min after sugar administration (1 g/kg p.o.), was 294.0 ± 5.9 mg/dL. A reduction of hematic
glycaemia was observed in the treated groups, at all times of the experiment. Indeed, 30 min after the
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beginning of the test, glucose levels of P. vulgaris extract, atorvastatin, and metformin-treated mice
were similar to those of normal diet control mice, while this value almost doubled in non-treated HFD
group. Next to the glucose tolerance test, the insulin tolerance test (ITT) was also performed at week 19
(Figure 2b). High fat diet-fed animals were resistant to insulin injection (1U/kg i.p.), as demonstrated
by stable glycaemic values 30 and 60 min following the administration, in comparison with the pre-test.
A slight, non-significant delayed response to insulin of HFD animals can be highlighted. The groups
treated with P. vulgaris extract and metformin were sensitive to the hormonal hypoglycaemic activity,
as explained by the reduced glycaemic values with respect to both the pre-test and the 30 min dosages
of the HFD controls. In the latter comparison, a one third reduction was observed, while in the
first comparison, there was a 22% and a 25% decrease due to P. vulgaris extract and metformin,
respectively. Atorvastatin treatment did not lower the tolerance to the insulin induced by high fat
diet. The evaluations of GTT and ITT were performed on fed animals according to the literature
which shows that the measure of glucose concentrations in fed state mice is informative as well as the
measure performed in fasted animal [28]. The values of the area under the curve (AUC) for GTT and
ITT were reported in Supplementary Table S2. The HOMA-IR values were also calculated and are
reported in Supplementary Table S3.
3.4. Plasma Enzymatic and Oxidative Parameters
During the last experimental week, insulin and ghrelin plasmic levels were measured. Insulin was
higher in HFD non-treated with respect to control animals. P. vulgaris extract and metformin lowered
that value in a significant way by about 80% (Table 2). Ghrelin plasmic values also appeared to be altered
in animals on high fat diet with respect to the control animals (10.5 ± 3.4 ng/mL vs. 38.6 ± 5.8 ng/mL,
respectively), and under treatment there was a trend to increase, but with no significance (Table 2).
Then, plasmatic alpha-amylase enzymatic activity was measured (Figure 2c). The fat-enriched diet
positively modulated enzyme activity with respect to the control levels, as it was almost unvaried in P.
vulgaris extract and metformin-treated groups. Atorvastatin administration was not able to lower the
high values induced by the high fat diet.
Table 2. Insulin and ghrelin levels.
Group
Normal Diet +
Vehicle HFD + Vehicle
HFD +
P. vulgaris
HFD +
Metformin
HFD +
Atorvastatin
Insulin
(ng/mL) 4.2 ± 0.5 46.1 ± 7.3 ** 8.9 ± 8.2 ˆˆ 10.2 ± 7.6 ˆˆ 34.9 ± 10.5
Ghrelin
(ng/mL) 38.6 ± 5.8 10.5 ± 3.4 * 17.0 ± 2.8 13.8 ± 4.3 15.8 ± 2.4
Effects of HFD and treatments on insulin and ghrelin plasma concentration at week 19. At week 19, HDL and LDL
values were also assessed. Animals were fed with normal or HFD diets from week 1. P. vulgaris extract (500 mg/kg),
metformin (100 mg/kg), and atorvastatin (10 mg/kg) were administered daily per os starting from week 11. Each
value represents the mean ± S.E.M. of at least 12 mice per group. * p < 0.05 and ** p < 0.01 vs. normal diet + vehicle;
ˆˆ p < 0.01 vs. HFD + vehicle.
Another parameter measured from plasma was protein carbonylation (Figure 3), which was
evaluated as integrated density (Figure 3a) from Western blot membranes (Figure 3b). Plasma from
HFD mice had a 45% increase of carbonylated proteins than plasma from control animals. That value
was reduced nearly to the control levels by chronic treatment with P. vulgaris extract.
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Figure 3. Plasmatic oxidation. Effects of HFD and treatments on the levels of carbonylated proteins
in plasma (week 19). Protein oxidative damage was quantified by immunoblot. (a) Densitometric
analysis and (b) representative Western blot are shown. Ponceau-stained membranes were used as
loading control. Results are expressed as % of control group (normal diet + vehicle; 100%). Each value
represents the mean ± S.E.M. of 12 mice per group. * p < 0.05 vs. normal diet + vehicle; ˆ p < 0.05 vs.
HFD + vehicle.
3.5. Behavioral Measurements
On week 19, behavioral measurements were also made, in order to highlight motorial and
neurological alterations due to the fat-enriched diet.
The Rota Rod test (Figure 4a) was used to evaluate motor coordination. The HFD animals fell
from two to three times more than the control animals throughout the one-hour exercise. Among all
the treatments, only P. vulgaris extract had restoring effects, making mice fall the same number
of times as the control animals. The Von Frey test evaluated mechanical allodynia evoked by a
non-noxious stimulus (Figure 4b). As shown by the graph, HFD mice demonstrated a significantly
lowered nociceptive threshold with respect to the control animals (1.2 ± 0.03 g vs. 1.5 ± 0.03 g,
respectively). Again, P. vulgaris extract treatment reverted this pain condition to the control threshold.
Other two behavioral tests, the plantar test (Supplementary Table S4) and the elevated plus maze test
(Supplementary Table S5), did not show significant alterations between the two control groups.
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Figure 4. Behavior. (a) The integrity of the animals’ motor coordination (week 19) was assessed
using a rota-rod apparatus. Rats were placed on a rotating rod (10 rpm) for 30 s every 15 min for 1 h.
The number of falls was counted. (b) The pain threshold was measured by the Von Frey test to assess
the response evoked by a mechanical non-noxious stimulus. Each value represents the mean ± S.E.M.
of 12 mice per group. * p <0.05 and ** p < 0.01 vs. normal diet + vehicle; ˆ p < 0.05 and ˆˆ p < 0.01 vs.
HFD + vehicle.
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3.6. Ex Vivo Analysis
At the end of the nineteenth week, the animals were sacrificed and some of their organs were
explanted for subsequent ex vivo analysis.
The heart, the liver, and the brain were weighed: the heart and the liver of non-treated HFD mice
had a higher weight than the organs of mice fed with a normal diet (Figure 5a,b). The administration of
P. vulgaris extract reduced the weight gain of the heart and liver ensuing the fat-enriched diet, reaching
a weight highly close to that of the control mice organs. Tissue weight of the liver, but not the heart,
was brought down also by metformin and atorvastatin administrations, but in a less remarkable way
than the food extract did: the latter reduced the weight by 40%, the drugs only by 30 and 20 percent,
respectively (Figure 5b). As to the brain, no significant alterations were observed when comparing
tissue weight of the different experimental groups (Supplementary Figure S1).
Figure 5. Organ weight. An week 19, after in vivo examinations, organs were collected and weighed.
(a) Heart; (b) liver. Each value represents the mean ± S.E.M. of 12 mice per group. ** p < 0.01 vs. normal
diet + vehicle; ˆ p < 0.05 and ˆˆ p < 0.01 vs. HFD + vehicle.
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Other histological and quantitative examinations were performed on the explanted tissues. As is
shown in Figure 6a, the hypercaloric diet caused a diffuse steatosis in the hepatic parenchyma, not
present in the liver of normal diet-fed mice. The pathological state was also expressed in numbers
by the steatosis index, as 9.66 ± 0.33 vs. 0.5 ± 0.1, referring to HFD and control mice, respectively
(Figure 6b). Another liver damage parameter to be evaluated was lipid peroxidation, expressed as
micromoles of thiobarbituric acid reactive substances (TBARS) per milligrams of protein present in
the sample. Feeding with fat-rich food caused a 40% more oxidative state of the lipidic component in
comparison to the control, while P. vulgaris extract treatment avoided the lipid peroxidation increase,
whose state was maintained similar to the control levels (Figure 6c).
Figure 6. Liver damage parameters. (a) Representative images of paraffin-embedded liver sections
(5 µm thickness), stained with hematoxyllin-eosin, 4X magnificated. (b) Quantitative expression of
steatosis index (graded ‘0’ to ‘10’ based on the average percent of fat-accumulated, 0 <5%, 10 >75%).
(c) Oxidative alteration. Lipid peroxidation was evaluated measuring TBARS (µmol/mg protein).
Week 19. Each value represents the mean ± S.E.M. of 12 mice per group. ** p < 0.01 vs. normal diet +
vehicle; ˆ p < 0.05 and ˆˆ p < 0.01 vs. HFD + vehicle.
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In Figure 7, four cardiac damage parameters are illustrated: the expression of catalase enzyme
(7a), glutathione reductase enzyme (7b), NADH dehydrogenase enzyme (7c), and the level of protein
carbonylation (7d). Catalase enzyme expression, involved in the detoxification of hydrogen peroxide,
appeared to be increased by 62% in the hearts of HFD mice and by 200% in those of HFD mice
challenged with P. vulgaris extract, in comparison with the control hearts. As to glutathione reductase,
which reduces oxidized endogen glutathione, its expression was positively modulated by a high
fat diet and by P. vulgaris extract administration. In the graph, the integrated density calculation
showed a 23% increased expression in the hearts of HFD mice and an 180% increase in those of HFD P.
vulgaris extract-treated mice. The third analyzed enzyme was NADH dehydrogenase, also named
Complex I, which transfers electrons from NADH to an acceptor in the mitochondrial respiratory
chain. The results show that the prolonged alimentation with high fat food stimulated a significative
increase of the enzyme expression with respect to the control. The integrated density calculated on
heart samples of the HFD animals increased by 120%, compared to the control. A decreasing trend, but
not statistically significant, was observed when the animals were challenged with P. vulgaris extract.
Eventually, protein carbonylation dosage gave a measure of the oxidative stress state of the heart.
Carbonylated proteins were 45% more in the heart of the HFD animals, compared to the control
animals, a condition which was not reduced in a significant way by P. vulgaris extract administration.
Figure 7. Cardiac damage parameters. Tissue homogenate was processed by Western blot in order to
evaluate the protein expression of (a) catalase; (b) glutathione reductase; (c) NADH dehydrogenase;
and (d) carbonylated proteins. Each parameter is reported as representative blot and densitometric
analysis. GAPDH normalization was performed for each sample. Results are expressed as % of control
group (normal diet + vehicle; 100%). Week 19. Each value represents the mean ± S.E.M. of 12 mice per
group. * p < 0.05 and ** p < 0.01 vs. normal diet + vehicle; ˆ p < 0.05 and ˆˆ p < 0.01 vs. HFD + vehicle.
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Next to the cardiac parameters, vascular system condition was also controlled. Oil Red O staining
made it possible to evaluate lipidic infiltrations in the aortic muscular layers (Figure 8a–d). HFD
feeding extensively augmented lipid infiltration in the aortic tissue, rather than normal alimentation
did (879 ± 66% vs 100 ± 15%, respectively). Sustained P. vulgaris challenges more than halved the lipid
deposit built up by high calories feeding.
Histological analysis was also made on epidydimal white adipose tissue. The photomicrographs
represent the effect of fat-enriched alimentation on the area of the adipocytes: The HFD adipocyte
mean area doubled the control mean area and P. vulgaris extract treatment did not lower significantly
the adipocyte enlargement (Figure 9a–d).
Figure 8. Vascular damage. (a–d) Evaluation of fatty streak infiltrations in aortic tissue of animals an
week 19. (a,b,d) Representative images of aortic arch sections stained with Oil-Red O, 20X magnificated.
(d) Quantitative determination of lesion extension, calculated as the positive area in comparison to
the total cross-sectional vessel wall area. Aortic damage is expressed as percentage in comparison to
control samples (set as 100%). ** p < 0.01 vs. normal diet + vehicle; ˆˆ p < 0.01 vs. HFD + vehicle.
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Figure 9. Adipose tissue damage. (a–d) Effects of diet and P. vulgaris treatment on white adipose tissue.
(a–c) Representative images of subcutaneous adipose tissue sections stained with hematoxylin-eosin,
20X magnificated. (d) Quantitative determination of adipocytes mean area (µm2) following HFD or P.
vulgaris administration. Each value represents the mean ± S.E.M. of 12 mice per group. **p < 0.01 vs.
normal diet + vehicle.
Morphologic analysis of renal tissue did not highlight any pathologic alteration between the
two differently fed group of animals: Both glomerular and mesangial regions showed unvaried area
measures with respect to the control (Supplementary Figure S2).
4. Discussion
The relevance of metabolic syndrome is due to the severity of the disorders that it involves:
Hyperglycaemia, insulin resistance, dyslipidaemia, obesity, atherogenic events, and hepatic steatosis.
All these hallmarks can easily lead to the onset of type 2 diabetes and cardiovascular problems.
Therefore, there is a real need for drugs able to target one or more of these disturbs, with few minor
side effects.
In the present study, we successfully produced a murine model of metabolic syndrome, in which
we investigated the protective effects of a standardized extract from P. vulgaris seeds. Its activity
was compared with two reference drugs, metformin and atorvastatin, that are used in clinical for
the management of hyperglycaemia and hypercholesterolemia, respectively. We obtained highly
encouraging results, as we demonstrated that the natural substance equalled and even sometimes
outdid the reference drug beneficial effects. The originality of our work consists in the evaluation of the
effect of an eight week daily treatment with a P. vulgaris extract on all hallmarks of metabolic syndrome,
ranging from the effect on blood glucose, triglycerides and cholesterol levels to the effect on pain and
motor alteration to the ex vivo analysis. We investigated the protective effect of P. vulgaris extract
repeated treatment on liver steatosis, on vascular damage, and on oxidative stress, highlighting that
the mechanism of action of P. vulgaris is due to its constituent phaseolamin, an alpha-amylase inhibitor.
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The onset of the syndrome was induced by high fat diet (HFD) feeding, containing 60% fats out of
the total calories, composed by animal fat and sucrose. The first induces metabolic disorders more
effectively than vegetable fat does, while the second exacerbates the correlated negative outcomes,
above all dyslipidaemia [29].
We firstly showed that P. vulgaris extract treatment significantly prevented the weight gain in HFD
mice, even more than treatment with the reference drugs. Several works on P. vulgaris extract reported
this anorexigenic effect, on diabetic and healthy rats, following acute or chronic administration in
ranging doses of 50–500 mg/kg. In such cases, it was supported by a concomitant reduction in food
intake [30,31], a condition which we did not observe. A cholecystokinin-mediated mechanism was
suggested [30] to explain the food intake decrease, nevertheless Reverri et al. [32] showed that the
increased plasmatic concentration of cholecystokinin in human subjects treated with a meal enriched
with black bean did not produce the expected heightened satiety.
Weight loss can be explained as independent of food intake: Fat reserves of HFD mice could
have been mobilized due to reduced total energy in form of glucose, whose plasmatic level was
lowered under treatment [17,33,34]. Some decades after its discovery, the alpha amylase inhibitor-1
phaseolamin was tested for anti-obesity starch-blocker effects on humans: Even if a significant weight
loss in obese and healthy subjects treated with the commercial αAI1 extract Phase 2TM was reported,
in other trials different commercial phaseolamin-based starch-blockers did not influence body weight.
Therefore, one could state that the anorexigenic effect is probably related to the maintenance of elevated
enzymatic anti-amylase activity and purity level of the compound, which in turn depends on extraction
and preparation methods of the starch-blocker commercial product [7].
We demonstrated that chronical administration of a P. vulgaris extract, containing alpha-amylase
inhibitor and phyto-haemagglutinin, had alleviating effects on three hallmarks of metabolic syndrome:
Hypercholesterolemia, hypertriglyceridemia, and hyperglycaemia. P. vulgaris extract behaved as a
hypocholesterolemic agent on HFD mice soon after two weeks of treatment: It produced results similar
to those obtained by the reference drug atorvastatin; moreover, it was the most efficient compound for
decreasing LDL values during the last experimental week, suggesting an increasing protective effect.
Similar studies on the bioactive natural compound, carried out on diabetic rats, did not highlight
any significant change in cholesterol levels [11], but a clinical open-label study on ten overweight
and hypercholesterolemic patients underlined a remarkable decrease of total cholesterol following
a prolonged treatment with granular food containing the P. vulgaris dry extract mixed with other
bioactive compounds [35]. A study conducted by Nunez-Aragon and colleagues indicated that total
hydrolysates and <1 kDa fractions from P. vulgaris showed antihyperglycemic activity, and this activity
was due to intestinal glucose absorption and α-glucosidase enzyme inhibition and was safe up to
5000 mg kg−1. Bean-derived protein hydrolysates and fractions may therefore have the potential to
be used in functional foods, dietary supplements, or pharmaceutical preparations for the prevention
and/or treatment of type 2 diabetes [36].
The beneficial effect of P. vulgaris extract treatment on blood triglycerides outdid the hypolipidemic
activity of metformin and equalled that of atorvastatin, effective a couple of weeks before the extract
and metformin.
The kidney extract was protective against hyperglycaemia, a result consistent with many studies
on rats (diabetic or healthy, fed with normal or starch-enriched diet), where different quantities of the
α-amylase inhibitor, chronically administrated from 10 to 20 days, induced a significant reduction of
glucose blood levels at the end of the prolonged treatment. In addition, when acutely administrated,
this lowering effect was observed on the post-prandial glycaemia levels, even if not always statistically
significant [17,33,34]. The efficacy on post-prandial hyperglycaemia was confirmed in humans by a
study of Spadafranca and her collaborators on healthy men and women, who were given a tablet
of P. vulgaris extract (containing both α-AI and phytohaemagglutinin; the same used in the present
study) to be ingested before a standardized meal [37]. Obesity is not only a matter of weight
gain, but behind that there are many other factors which predispose to diabetes and cardiovascular
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diseases. A low-grade chronic inflammation ensues the pro-inflammatory activity of obesity-induced
hypertrophied adipocytes and inflammatory cells, and along with increased free fatty acids they alter
insulin receptor pathway, till its inhibition [38]. In our study, the HFD provoked an impaired response
to both glucose and insulin, confirming the two typical resistance forms of metabolic syndrome.
We showed that P. vulgaris extract treatment significantly alleviated both tolerances; metformin showed
a similar profile, whereas atorvastatin was effective in preventing the altered response to glucose
load only. Insulin hormone is crucial in glucose and lipid metabolism and it is also related to the
satiety pathway of central and peripheral nervous system: A hampered response of the nervous
insulin receptors was reported to be related to appetite control, leading to hyperphagia and obesity.
In addition, chronic hyperinsulinemia generally occurring in obese patients appears to function as a
compensatory strategy of our organism, in order to restore energy reserves and to limit weight gain [39].
In our experiments, HFD mice at the 19th week of the enriched diet had high insulin plasmatic levels
remarkably lowered by P. vulgaris extract and metformin treatment, in an almost identical way.
Ghrelin is another hormone thought to have a prominent role in obesity and metabolic syndrome.
Ghrelin is a stomach-derived peptide hormone, produced by the endocrine cells of the oxyntic mucosa,
which regulates appetite. Its levels increase before a meal and decrease soon after ending a meal; this
post-prandial suppression communicates satiety and food reward to the central nervous system (CNS).
Although fasting ghrelin levels of obese individuals are lower than those of lean people, the absence
of a physiological decrease after a meal explains their non-stop eating behavior [37,39]. In her paper,
Spadafranca and her collaborators sustained the hypothesis of a link between ghrelin suppression and
P. vulgaris extract administration [37]. In our study we cannot confirm this: Non-treated HFD mice had
low ghrelin levels, but hormonal secretion appeared not to be influenced by the prolonged P. vulgaris
extract treatment; ghrelin levels increased without reaching a statistical significance.
The results of the present study stressed another mechanism, the ability of P. vulgaris extract to
negatively modulate enzymatic activity of pancreatic alpha-amylase, which in extract-treated HFD
mice almost reached the levels of controls. Phaseolamin is, indeed, commonly recognized as a starch
blocker, a compound which slows down the digestion of complex carbohydrates, and thus gastric
emptying as well, due to the inhibition of α-amylase enzymatic activity [7,37,40].
A growing body of literature links prediabetes, obesity, and metabolic syndrome to the risk of
diabetic peripheral neuropathy as well as cryptogenic sensory peripheral neuropathy [41]. On this
basis, we focused on neurological impairments; in the HFD group we observed a decreased pain
threshold, highlighting a condition that resembles mechanical allodynia, as well as altered motor
coordination. Interestingly, these alterations were reverted only in the P. vulgaris extract treated-group.
This point could be explained since phytotherapy is based on the combined action of a mixture of
constituents able to offer a multiple approach to the multi-factorial nature of the metabolic syndrome.
The bioactivity of crude drugs or vegetal extracts is a summation of antagonistic and/or synergistic
effects on bioavailability, cellular transport processes, compound metabolism, and pharmacodynamic
mechanisms, which could explain the positive effect of P. vulgaris extract also on pain threshold and
motor alterations induced by HFD. On the contrary, metformin and atorvastatin, two drugs with
a specific function and mechanism of action, are ineffective. No effects on thermal hyperalgesia or
anxiety were recognized in HFD-fed animals. A similar annotation of metabolic syndrome fallouts on
neurological behavior was published in a work by Takase and his colleagues, who observed that HFD
evoked motorial disfunctions in mice, with no influences on anxiety [42].
A fat-enriched diet considerably affects the liver, the organ dedicated to lipid and lipoprotein
metabolism, in addition to—and because of—the onset of glucose and insulin resistance. The increased
circulating free fatty acids overload the liver with fat and cholesterol, causing hepatotoxicity, a state of
dyslipidemia, excess fat deposing and cardiovascular diseases. In particular, the fatty diet and insulin
resistance cause a switch from the physiological mitochondrial lipid oxidation to peroxidation of long
chain fatty acids, which promotes lipotoxicity and extraordinary release of reactive oxygen species
(ROS) [43].
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The high fat diet caused a gain weight of liver and heart in the HFD mice, but it was significantly
lowered by treatment with P. vulgaris extract. Also, the other steps of on-going metabolic syndrome
were confirmed. Histological samples from the HFD group clearly showed hepatosteatosis, hepatic
lipid peroxidation, and lipid accumulation in the cardiovascular system, such as the fatty streaks in the
aorta. These disease-related negative consequences were reverted by P. vulgaris extract challenge.
As mentioned above, the excessive generation of ROS, when not counterbalanced by the antioxidant
mechanisms, is a pathological condition which is dramatically augmented in metabolic syndrome, thus
inducing the antioxidant defense system to change in relation to the new state. Protein carbonylation
in the plasma, normally increased in a fat diet, was significantly reduced in P. vulgaris extract -treated
mice, showing a protective role of the compound against this oxidative stress consequence. Conversely,
it was not sufficient to protect the HFD heart, whose carbonylated proteins were not significantly
diminished by the same treatment.
Aiming to study possible redox detoxifying mechanisms, we evaluated the expression levels
of cardiac antioxidant enzymes. Catalase and GSH reductase were considerably more expressed in
HFD hearts, probably obeying to a pathophysiological compensatory mechanism, to face the elevated
cardiac ROS levels. P. vulgaris extract treatment raised the levels of all the antioxidant enzymes, except
for NADH dehydrogenase which was slightly reduced.
5. Conclusions
The present standardized P. vulgaris extract counteracts molecular, biochemical, and behavioral
alterations induced by HFD in a clinically-relevant model of metabolic syndrome. The wide range of
activity, as well as the well assessed safety profile [40], makes P. vulgaris extract an intriguing candidate
for a clinical use.
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